Notes from the June 30-July 1 Meeting of the IOM Committee on the Use of Omics-Based Markers in Clinical Trials
This web page is designed to hold files from the third meeting
of the IOM Committee examining the use of Omics-based signatures
in clinical trials. Some case studies related to the formation
of this committee are presented in the manuscript Deriving
Chemosensitivity from Cell
Lines: Forensic Bioinformatics and Reproducible Research in High-Throughput
Biology by Keith A. Baggerly and Kevin R. Coombes (the main page
is here) and Subsequent Reports
(available here).
Session Description and Agenda
The June 30-July 1 meeting of the IOM Omics committee
was mostly in closed session. The only open session
presentation involved a discussion with Lisa McShane
of the NCI.
MP3 Files of McShane Discussion Session
1. Part 1
1 hr, 55 min, 55 sec; 55.6 Mb
2. Part 2
23 min, 25 sec; 11.2 Mb
Files Mentioned in the Discussion
Slides from Dr. McShane
dealing with challenges in evaluating genomic
predictors.
Letter from David Beer
alluded to by Dan Hayes.
The discussion mentions a meeting between
members of the committee and Dr. McShane that took
place on Jun 21st ("an extraordinary meeting").
Summary Notes from Jun 21 Mtg.
Other files may eventually appear on the IOM's
web page for this session.